ThompsonAJBaranziniSEGeurtsJ, et al. Multiple sclerosis. Lancet2018; 391: 1622–1636.
2.
HartungHPMeuthSGThompsonAJ. Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis. Mult Scler2021; 27(10): 1473–1476.
3.
HauserSL. Curing multiple sclerosis: How to know when we’re there. Ann Neurol. Epub ahead of print 2 July 2021. DOI: 10.1002/ana.26155.
4.
Pulido-ValdeolivasIAndorraMGomez-AndresD, et al. Retinal and brain damage during multiple sclerosis course: Inflammatory activity is a key factor in the first 5 years. Sci Rep2020; 10: 13333.
5.
AndorraMNakamuraKLampertEJ, et al. Assessing biological and methodological aspects of brain volume loss in multiple sclerosis. JAMA Neurology2018; 75: 1246–1255.
6.
PopescuVAgostaFHulstHE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry2013; 84(10): 1082–1091.
7.
Pulido-ValdeolivasIZubizarretaIMartinez-LapiscinaE, et al. Precision medicine for multiple sclerosis: An update of the available biomarkers and their use in therapeutic decision making. Expert Rev Precis Med Drug Dev2017; 2: 1–17.
8.
UherTHavrdovaEBenkertP, et al. Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Mult Scler2021; 27(13): 2001–2013.
9.
KalincikTCutterGSpelmanT, et al. Defining reliable disability outcomes in multiple sclerosis. Brain2015; 138(Pt. 11): 3287–3298.
10.
BarroCBenkertPDisantoG, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain2018; 141: 2382–2391.
